Epoetin Beta

CHEMBL2109092 Phase 4 Aprovado Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This synthetic version of the natural hormone erythropoietin stimulates red blood cell production in people with anemia caused by chronic kidney disease or cancer treatment. It is given by injection at regular intervals.

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This synthetic version of the natural hormone erythropoietin stimulates red blood cell production in people with anemia caused by chronic kidney disease or cancer treatment. It is given by injection at regular intervals.

Yes, Epoetin Beta is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109092. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.